Pharming Group (NASDAQ:PHAR) Shares Up 5.7% – What’s Next?

Pharming Group (NASDAQ:PHAR) shares traded up 5.7% during mid-day trading on Thursday . The company traded as high as $8.76 and last traded at $8.90. 1,935 shares traded hands during trading, a decline of 60% from the average session volume of 4,843 shares. The stock had previously closed at $8.42.

Analyst Upgrades and Downgrades

PHAR has been the topic of several recent analyst reports. Oppenheimer reduced their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a research report on Monday, October 28th. Jefferies Financial Group began coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th.

Pharming Group Price Performance

The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $594.51 million, a PE ratio of -33.55 and a beta of -0.10. The firm’s 50 day simple moving average is $9.16 and its 200 day simple moving average is $8.43.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its holdings in shares of Pharming Group (NASDAQ:PHAR) by 16.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. 0.03% of the stock is currently owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.